OSI-420

OSI-420は、人間のEGFRとEGFR自己リン酸化の抑制のための経口で有効なEGFR チロシンキナーゼ阻害剤であるErlotinibの活性代謝物質で、IC50 がそれぞれ 2 nM と 20 nMです。

目録号S2205
5 5 1レビュー 2製品表彰状
価格 在庫  
USD 214 In stock
USD 352 In stock
USD 403 In stock
USD 970 In stock
USD 2104 In stock

OSI-420 化学構造
分子量: 415.87

品質と確認

カスタマーレビュー(1)

Quality Control & MSDS

製品情報

製品の説明

生物活性

情報 OSI-420は、人間のEGFRとEGFR自己リン酸化の抑制のための経口で有効なEGFR チロシンキナーゼ阻害剤であるErlotinibの活性代謝物質で、IC50 がそれぞれ 2 nM と 20 nMです。
目標 EGFR
IC50 2 nM [1]
In vitro試験 OSI-420 is the major metabolite of Erlotinib in human plasma. Erlotinib disappearance from plasma after a short IV infusion is biexponential with a mean terminal half-life of 5.2 h and a mean clearance of 128 ml/min per m(2). OSI-420 exposure (AUC) in plasma is 30% (range 12-59%) of erlotinib, and OSI-420 clearance is more than 5-fold higher than erlotinib. Erlotinib and OSI-420 are equipotent, and the combined concentrations of erlotinib + OSI-420 achieved in the CSF exceeded the IC50 (7.9 ng/ml or 20 nM) for the EGFR tyrosine kinase inhibition in intact tumor cells. [1] Erlotinib potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib (1 μM) induces apoptosis in DiFi humancolon cancer cells. [2] Erlotinib growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. [3] Erlotinib(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. [4] The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. [5] Combination with Erlotinib could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition. [6]
In vivo試験 At doses of 100 mg/kg, Erlotinib completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. [1] Erlotinib reduces the growth of xenografted human AML cells. [4]
臨床試験 Erlotinib has entered in a phase II clinical trial in the treatment of primary sclerosing cholangitis, cholangiocarcinoma and chemoprevention.
特集 OSI 420 is a major active metabolite of Erlotinib.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

Kinase Assays 96-well plates are coated by incubation overnight at 37 °C with 100 μL per well of 0.25 mg/mL PGT in PBS. Excess PGT is removed by aspiration, and the plate is washed 3 times with washing buffer (0.1% Tween 20 in PBS). The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3), containing 125 mM sodium chloride, 24 mM magnesium chloride, 0.1 mM sodium orthovanadate, 20 μM ATP, 1.6 μg/mL EGF, and 15 ng of EGFR, affinity purified from A431 cell membranes. Erlotinib HCl in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 minutes at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with washing buffer. Phosphorylated PGT is measured by 25 minutes of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with washing buffer. The colonmetric signal is developed by addition of TMB Microwell Peroxidase Substrate, 50μL per well, and stopped by the addition of 0.09 M sulfuric acid, 50 μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no back ground in wells without AlP, EGFR, or PGT and is proportional to the time of incubation for 10 minutes.

細胞アッセイ: [3]

細胞系 A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 cells
濃度 30 nM-20 μM
処理時間 72 hour
方法 Exponentially growing cells are seeded in 96-well plastic plates and exposed to serial dilutions of erlotinib, pemetrexed, or the combination at a constant concentration ratio of 4:1 in triplicates for 72 h. Cell viability is assayed by cell count and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Growth inhibition is expressed as the percentage of surviving cells in drug-treated versus PBS-treated control cells (which is considered as 100% viability). The IC50 value is the concentration resulting in 50% cell growth inhibition by a 72-h exposure to drug(s) compared with untreated control cells and is calculated by the CalcuSyn software.

動物実験: [7]

動物モデル Male 5-week-old BALB-nu/nu with HPAC
製剤 6% Captisol
投薬量 50 mg/kg
管理 Oral administration
1

参考

化学情報

Download OSI-420 SDF
分子量 415.87
化学式

C21H21N3O4.HCl

CAS No. 183320-51-6
別名 CP-473420
溶解度 (25°C)
  • DMSO 83 mg/mL heat
  • 水 <1 mg/mL
  • エタノール <1 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 2-(4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinazolin-6-yloxy)ethanol hydrochloride

研究分野

カスタマーレビュー (1)


Click to enlarge
Rating
Source Sci Pharm, 2012, 80(3), 633-646 . OSI-420 purchased from Selleck
Method LC-MS/MS analysis
Cell Lines Wistar rats
Concentrations 1.5-1150 ng/mL
Incubation Time 24 h, 12h
Results An LC-MS/MS bioanalytical method for the simultaneous determination of three analytes, CCB, ERT, and OSI-420, was developed and validated in rat plasma. The method was good enough to detect the low concentration of 1.5 ng/mL for all analytes in 50 µL rat plasma, and can further be improved by increasing the plasma volume.

製品表彰状 (2)

  • Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. [Dong Z, et al. Carcinogenesis 2010;31(11), 1948-1955]

    PubMed: 20837598
  • Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation. [Thappali SR, et al. Sci Pharm 2012;80(3):633-46]

    PubMed: 23008811

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related EGFR 阻害剤

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992)は不可逆的にEGF受容体/ HER2含むEGF受容体を抑制、 EGFR L858R , EGFR L858R/T790M と HER2を作用すると、 IC50がそれぞれ0.5 nM, 0.4 nM, 10 nM, 14 nMとなる。

  • Canertinib (CI-1033)

    Canertinib (CI-1033) は有効的に チロシンキナーゼを抑制で、 EGFR と erbB2 を作用する時IC50 はそれぞれ 1.5 nM と 9.0 nMになる.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744)は、2nMのIC50によるHER1/EGFR阻害剤です。

  • Gefitinib (ZD1839)

    Gefitinib (ZD1839) は、NR6wtEGFRとNR6W細胞のTyr1173、Tyr992、Tyr1173とTyr992のためのEGFR阻害剤で、IC50 がそれぞれ 37 nM、 37nM、 26 nM 、57 nMです。

  • Lapatinib (GW-572016) Ditosylate

    Lapatinib (GW-572016) Ditosylateは有効EGFRとErbB2阻害剤、IC50それぞれ10.8と9.2nM。

  • AC480 (BMS-599626)

    AC480 (BMS-599626)は、HER1とHER2の選択的で口で有効な阻害剤で、IC50 がそれぞれ 20 nM と 30 nMです。

  • PD153035 HCl

    PD153035 HClは、EGFRの強力で特定の阻害剤で、Ki と IC50 がそれぞれ 5.2 pM と 29 pMです。

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42)は、EGFRの選択的な阻害剤、ErbB2とJAK2で、IC50 がそれぞれ 0.1 μM、 13.5 μM、 and ~10 μMです。

  • CP-724714

    CP-724714は、10nMのIC50によるerbB2の強力な、選択的な阻害剤です。

  • WZ3146

    WZ3146は、EGFR(L858R)とEGFR(E746_A750)の変異体選択元に戻らない阻害剤で、IC50 がそれぞれ 2 nM と 2 nMです。

最近見られたアイテム

Tags: OSI-420を買う | OSI-420供給者 | OSI-420を購入する | OSI-420費用 | OSI-420生産者 | オーダーOSI-420 | OSI-420代理店
お問い合わせ